A US plant that was making Johnson & Johnson’s COVID-19 vaccine

Cape May County - A US plant that was making Johnson & Johnson’s COVID-19 vaccine must fix a long list of problems including peeling paint and unsanitary conditions and practices to resume operation, according to a highly critical report by the Food and Drug Administration. Experts said addressing the issues raised in the scathing FDA inspection report could take months. J&J nor the FDA has said when they expect vaccine production to restart at the Baltimore plant owned by Emergent Biosolutions. Only two other plants are currently equipped to supply the world with the key drug substance for J&J’s vaccine.